New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Video animation guide to help young people living with cancer-related fatigue

Video animation guide to help young people living with cancer-related fatigue

byUniversity of BathCredit: University of BathA new resource has been launched by a team of psychologists at the University of Bath aiming to help young people living with cancer-related fatigue
Oncology January 04,2024
Video animation guide to help young people living with cancer-related fatigue

Video animation guide to help young people living with cancer-related fatigue

byUniversity of BathCredit: University of BathA new resource has been launched by a team of psychologists at the University of Bath aiming to help young people living with cancer-related fatigue
Oncology January 04,2024
Retinol disruption and the role of vitamin A metabolism in colon cancer

Retinol disruption and the role of vitamin A metabolism in colon cancer

by Impact Journals LLCRetinol-mediated suppression of tumor-promoting IL-6 is disrupted in colon cancer-associated fibroblasts. Credit: 2023 Villéger et al.A new research perspective was published in&
Oncology January 04,2024
Retinol disruption and the role of vitamin A metabolism in colon cancer

Retinol disruption and the role of vitamin A metabolism in colon cancer

by Impact Journals LLCRetinol-mediated suppression of tumor-promoting IL-6 is disrupted in colon cancer-associated fibroblasts. Credit: 2023 Villéger et al.A new research perspective was published in&
Oncology January 04,2024
Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term an
Oncology January 04,2024
Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term an
Oncology January 04,2024
Trial shows promise for new antibody cancer treatment

Trial shows promise for new antibody cancer treatment

byKing's College LondonMechanism of cytotoxicity mediated by MOv18 IgE. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-39679-9The first ever clinical trial of a new
Oncology January 04,2024
Trial shows promise for new antibody cancer treatment

Trial shows promise for new antibody cancer treatment

byKing's College LondonMechanism of cytotoxicity mediated by MOv18 IgE. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-39679-9The first ever clinical trial of a new
Oncology January 04,2024
Trial demonstrates acute lymphoblastic leukemia treatment advance

Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas
Oncology January 04,2024
Trial demonstrates acute lymphoblastic leukemia treatment advance

Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas
Oncology January 04,2024
Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainA Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment wi
Oncology January 04,2024
Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainA Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment wi
Oncology January 04,2024
Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

byDana-Farber Cancer InstituteNew research shows that genetics account for only five to 10 per cent of risk for most human diseases, and that gene testing is a poor predictor of whether someone
Oncology January 04,2024
Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

byDana-Farber Cancer InstituteNew research shows that genetics account for only five to 10 per cent of risk for most human diseases, and that gene testing is a poor predictor of whether someone
Oncology January 04,2024
Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva
Oncology January 04,2024
Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva
Oncology January 04,2024
Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs
Oncology January 04,2024
Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs
Oncology January 04,2024
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,
Oncology January 04,2024
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,
Oncology January 04,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com